Sofie signs deal with ABX for cGMP compliance

Molecular imaging developer Sofie Biosciences has signed an agreement with ABX Advanced Biochemical Compounds of Radeberg, Germany, for ABX to provide Sofie with current good manufacturing practice (cGMP) precursor and reference standards for Sophie's fibroblast activation protein inhibitor (FAPI) compounds.

Sofie said the deal will support its ongoing clinical development of these compounds.

Page 1 of 551
Next Page